Sort by

Send to

Choose Destination

Links from PubMed

Items: 12


Binding Studies of TNF Receptor Superfamily (TNFRSF) Receptors on Intact Cells.

Lang I, Füllsack S, Wyzgol A, Fick A, Trebing J, Arana JA, Schäfer V, Weisenberger D, Wajant H.

J Biol Chem. 2016 Mar 4;291(10):5022-37. doi: 10.1074/jbc.M115.683946. Epub 2015 Dec 31.


Galectin-9 controls the therapeutic activity of 4-1BB-targeting antibodies.

Madireddi S, Eun SY, Lee SW, Nemčovičová I, Mehta AK, Zajonc DM, Nishi N, Niki T, Hirashima M, Croft M.

J Exp Med. 2014 Jun 30;211(7):1433-48. doi: 10.1084/jem.20132687. Epub 2014 Jun 23.


SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines.

Sharma RK, Yolcu ES, Shirwan H.

Expert Rev Vaccines. 2014 Mar;13(3):387-98. doi: 10.1586/14760584.2014.880340. Review.


CD4+ T cells play a critical role in the generation of primary and memory antitumor immune responses elicited by SA-4-1BBL and TAA-based vaccines in mouse tumor models.

Sharma RK, Yolcu ES, Srivastava AK, Shirwan H.

PLoS One. 2013 Sep 16;8(9):e73145. doi: 10.1371/journal.pone.0073145. eCollection 2013.


A functional recombinant human 4-1BB ligand for immune costimulatory therapy of cancer.

Meseck M, Huang T, Ma G, Wang G, Chen SH, Woo SL.

J Immunother. 2011 Mar;34(2):175-82. doi: 10.1097/CJI.0b013e318206dac1.


SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model.

Sharma RK, Srivastava AK, Yolcu ES, MacLeod KJ, Schabowsky RH, Madireddi S, Shirwan H.

Vaccine. 2010 Aug 16;28(36):5794-802. doi: 10.1016/j.vaccine.2010.06.073. Epub 2010 Jul 4.


4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines.

Sharma RK, Schabowsky RH, Srivastava AK, Elpek KG, Madireddi S, Zhao H, Zhong Z, Miller RW, Macleod KJ, Yolcu ES, Shirwan H.

Cancer Res. 2010 May 15;70(10):3945-54. doi: 10.1158/0008-5472.CAN-09-4480. Epub 2010 Apr 20.


The structure of the trimer of human 4-1BB ligand is unique among members of the tumor necrosis factor superfamily.

Won EY, Cha K, Byun JS, Kim DU, Shin S, Ahn B, Kim YH, Rice AJ, Walz T, Kwon BS, Cho HS.

J Biol Chem. 2010 Mar 19;285(12):9202-10. doi: 10.1074/jbc.M109.084442. Epub 2009 Dec 23.


A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity.

Schabowsky RH, Elpek KG, Madireddi S, Sharma RK, Yolcu ES, Bandura-Morgan L, Miller R, MacLeod KJ, Mittler RS, Shirwan H.

Vaccine. 2009 Dec 11;28(2):512-22. doi: 10.1016/j.vaccine.2009.09.127. Epub 2009 Oct 29.


ProtEx technology for the generation of novel therapeutic cancer vaccines.

Schabowsky RH, Sharma RK, Madireddi S, Srivastava A, Yolcu ES, Shirwan H.

Exp Mol Pathol. 2009 Jun;86(3):198-207. doi: 10.1016/j.yexmp.2009.01.010. Epub 2009 Jan 31. Review.


Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors.

Sharma RK, Elpek KG, Yolcu ES, Schabowsky RH, Zhao H, Bandura-Morgan L, Shirwan H.

Cancer Res. 2009 May 15;69(10):4319-26. doi: 10.1158/0008-5472.CAN-08-3141. Epub 2009 May 12.


Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain.

Morris NP, Peters C, Montler R, Hu HM, Curti BD, Urba WJ, Weinberg AD.

Mol Immunol. 2007 May;44(12):3112-21. Epub 2007 Mar 19.

Items per page

Supplemental Content

Support Center